From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

Area of Science:

• Hematology
• Pharmacology
• Internal Medicine

Background:

• Iron chelation therapy (ICT) is crucial for managing iron overload (IOL) in transfusion-dependent hematological patients, primarily thalassemic and low-risk Myelodysplastic Syndrome (MDS) patients.
• Emerging evidence suggests ICT's potential benefit for high-risk MDS patients, particularly those undergoing allogeneic bone marrow transplantation.
• Iron toxicity, driven by oxidative stress from free iron species, can worsen anemia and comorbidities in various hematological conditions requiring transfusion support.

Purpose of the Study:

• To identify non-thalassemic patient populations who can benefit from iron chelation therapy.
• To provide practical recommendations for the management of ICT in a broader range of hematological disorders.
• To highlight the expanding role of ICT in managing iron overload and its associated complications.

Main Methods:

• Review of existing literature on iron chelation therapy in hematological disorders.
• Analysis of data regarding iron toxicity mechanisms, including oxidative stress and radical oxygen species (ROS).
• Evaluation of the efficacy and safety of approved oral iron chelators.

Main Results:

• ICT is established in thalassemia and low-risk MDS, with growing consideration for high-risk MDS.
• Iron toxicity exacerbates anemia and comorbidities through ROS-mediated oxidative stress.
• Availability of oral iron chelators supports wider application of ICT.

Conclusions:

• Iron chelation therapy is poised for increased utilization across diverse hematological conditions.
• Identifying non-thalassemic patients eligible for ICT is essential for optimizing treatment outcomes.
• Effective management strategies are crucial for maximizing the benefits of ICT and preventing organ damage.